Kiichiro Ninomiya
Okayama University · 204 works · 1,926 citations · h-index 23
Top works
- Trastuzumab Deruxtecan in Patients With HER2 -Mutant Metastatic Non–Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial
- A Phase II Study of Trastuzumab Emtansine in HER2-Positive Non–Small Cell Lung Cancer
- The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV
- A suspected case of rocuronium–sugammadex complex-induced anaphylactic shock after cesarean section
- Congestive Heart Failure During Osimertinib Treatment for Epidermal Growth Factor Receptor (EGFR)-mutant Non-small Cell Lung Cancer (NSCLC)
- The effect and safety of immune checkpoint inhibitor rechallenge in non-small cell lung cancer
- VEGFR2 blockade augments the effects of tyrosine kinase inhibitors by inhibiting angiogenesis and oncogenic signaling in oncogene‐driven non‐small‐cell lung cancers
- 1321MO Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2 (ERBB2)-mutant (HER2m) metastatic non–small cell lung cancer (NSCLC) with and without brain metastases (BMs): Pooled analyses from DESTINY-Lung01 and DESTINY-Lung02
- Rapid Acquisition of Alectinib Resistance in ALK-Positive Lung Cancer With High Tumor Mutation Burden
- MET or NRAS amplification is an acquired resistance mechanism to the third-generation EGFR inhibitor naquotinib
- Trastuzumab Emtansine in HER2+ Recurrent Metastatic Non–Small-Cell Lung Cancer: Study Protocol
- A Prospective Cohort Study to Define the Clinical Features and Outcome of Lung Cancers Harboring HER2 Aberration in Japan (HER2-CS STUDY)
- Clinical significance of repeat rebiopsy in detecting the EGFR T790M secondary mutation in patients with non-small cell lung cancer
- Short-term low-volume hydration in cisplatin-based chemotherapy for patients with lung cancer: the second prospective feasibility study in the Okayama Lung Cancer Study Group Trial 1201
- Severe Cytokine Release Syndrome and Immune Effector Cell-associated Neurotoxicity Syndrome in a Man Receiving Immune Checkpoint Inhibitors for Lung Cancer
- Influence of age on the efficacy of immune checkpoint inhibitors in advanced cancers: a systematic review and meta-analysis
- The effect and safety of an immune checkpoint inhibitor rechallenge in non-small cell lung cancer.
- Japanese Lung Cancer Society Guidelines for Stage IV NSCLC With EGFR Mutations
- Re-administration of osimertinib in osimertinib-acquired resistant non-small-cell lung cancer
- Utility of immune checkpoint inhibitors in non‐small‐cell lung cancer patients with poor performance status